DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California. The markets expect FOMC to cut but outlook in 2025 is less certainMarkets expect a 25bp rate cut at the FOMC meeting on December 18, 2024, amid strong U.S. economic data. However, the outlook for 2025 remains uncertain as inflation and growth trends evolve.
12:20, 17 December 2024
Pi Network coin price prediction: Third party price targetDiscover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
12:20, 13 December 2024
Projected US interest rates in 5 years: Third party round upAs the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
08:24, 13 December 2024
Projected UK interest rates in 5 yearsBank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
12:28, 12 December 2024